212 related articles for article (PubMed ID: 26560143)
1. Absolute Quantification of Endogenous Ras Isoform Abundance.
Mageean CJ; Griffiths JR; Smith DL; Clague MJ; Prior IA
PLoS One; 2015; 10(11):e0142674. PubMed ID: 26560143
[TBL] [Abstract][Full Text] [Related]
2. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
3. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
4. Isoform-specific Ras signaling is growth factor dependent.
Hood FE; Klinger B; Newlaczyl AU; Sieber A; Dorel M; Oliver SP; Coulson JM; Blüthgen N; Prior IA
Mol Biol Cell; 2019 Apr; 30(9):1108-1117. PubMed ID: 30785867
[TBL] [Abstract][Full Text] [Related]
5. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
6. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
7. A model for RAS mutation patterns in cancers: finding the sweet spot.
Li S; Balmain A; Counter CM
Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
[TBL] [Abstract][Full Text] [Related]
8. Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation.
Ikonomou G; Kostourou V; Shirasawa S; Sasazuki T; Samiotaki M; Panayotou G
J Proteomics; 2012 Sep; 75(17):5356-69. PubMed ID: 22800643
[TBL] [Abstract][Full Text] [Related]
9. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
10. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
12. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium.
Keller JW; Franklin JL; Graves-Deal R; Friedman DB; Whitwell CW; Coffey RJ
J Cell Physiol; 2007 Mar; 210(3):740-9. PubMed ID: 17133351
[TBL] [Abstract][Full Text] [Related]
14. Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations.
Hammond DE; Mageean CJ; Rusilowicz EV; Wickenden JA; Clague MJ; Prior IA
J Proteome Res; 2015 Mar; 14(3):1535-46. PubMed ID: 25599653
[TBL] [Abstract][Full Text] [Related]
15. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
16. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
17. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
[TBL] [Abstract][Full Text] [Related]
18. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
Nakhaeizadeh H; Amin E; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
PLoS One; 2016; 11(12):e0167145. PubMed ID: 27936046
[TBL] [Abstract][Full Text] [Related]
19. Rare codons regulate KRas oncogenesis.
Lampson BL; Pershing NL; Prinz JA; Lacsina JR; Marzluff WF; Nicchitta CV; MacAlpine DM; Counter CM
Curr Biol; 2013 Jan; 23(1):70-5. PubMed ID: 23246410
[TBL] [Abstract][Full Text] [Related]
20. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
